ACT16482: Phase 1-2 Trial Evaluating Anti-TGFB; Agent (SAR439459) or Pomalidomide in Combination with Isatuximab and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM)

The following study has recently been activated for patient enrollment by The University of Illinois Cancer Center Clinical Trials Office (CTO). Click on the link to learn about the details regarding the study on clinicaltrials.gov. For more information or questions about a study, email cancertrials@uic.edu or call 312-355-5112.

ACT16482: Phase 1-2 Trial Evaluating Anti-TGFB; Agent (SAR439459) or Pomalidomide in Combination with Isatuximab and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM)

Sponsor: Sanofi
Principal Investigator: Sean Quigley, MD